📰 Ingo Mellinghoff News
Page 2 - Ingo Mellinghoff News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ingo Mellinghoff. Real-time updates on events, politics, business and more.
June 4, 2023
A study co-led by UCLA is the first clinical trial analyzing a targeted therapy specifically developed to treat brain tumors.
June 4, 2023
Vorasidenib demonstrated an unprecedented improvement in progression free survival with a median of 27.7 months in patients with residual or recurrent grade 2...
June 4, 2023
Miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
June 4, 2023
Kansascity.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kansascity.com Daily Mail and Mail on Sunday newspapers.
June 4, 2023
A Servier drug candidate acquired as part of a $1.8 billion deal kept a particular type of brain cancer from progressing in a Phase 3 clinical trial. The study results were presented during the 2023 annual meeting of the American Society of Clinical Oncology.
March 11, 2021
Summary Neuro-oncologist Ingo Mellinghoff first became intrigued by scientific questions regarding brain tumors while working in the lab of physician-scientist Charles Sawyers before both came to MSK. Now, Dr. Mellinghoff leads MSK’s Department of Neurology as it deploys innovative technologies to understand how these cancers develop and progress. When neuro-oncologist Ingo Mellinghoff was named Chair of Memorial Sloan Kettering’s Department of Neurology in October 2020, it marked the culm...
January 7, 2021
ASX RELEASE 7 January 2021 GBM AGILE PIVOTAL STUDY COMMENCES RECRUITMENT TO PAXALISIB ARM Sydney, 7 January 2021 -... | January 27, 2021
January 7, 2021
Posted on 288 Global Coalition for Adaptive Research (LOS ANGELES, CA), Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA, SYDNEY, Australia), and Kintara Therapeutics, Inc. (NASDAQ: KTRA, SAN DIEGO, CA) — The Global Coalition for Adaptive Research (GCAR) in collaboration with Kazia and Kintara, today announced the activation of Kazia’s paxalisib and Kintara’s VAL-083 in GBM AGILE (Glioblastoma Adaptive Global Innovative Lea...